This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Stefaan De Koker, PhD
Vice President, Discovery at eTheRNA Immunotherapies

Profile

Stefaan De Koker obtained his PhD at the lab for Molecular Immunology at Ghent University. During his academic career at VIB, he worked on unraveling how early activation of the innate immune system by adjuvants shapes adaptive immunity to vaccines. Stefaan became early involved in the mRNA therapeutics field and published seminal papers on the mode-of-action of mRNA vaccines, on the usage of mRNA for intratumoral immunomodulation and on the development of novel delivery vehicles for mRNA therapeutics. September 2016, Stefaan joined eTheRNA where he leads the discovery team with the aim to improve the immunogenicity of in situ applied mRNA cancer immunotherapies and to design tailored LNP solutions. Stefaan has authored over 60 publications and is co-inventor on >10 patent applications.

Agenda Sessions

  • EL-201: a systemic mRNA LNP Vaccine for the Treatment of HPV16+ Cancers

    10:30